share_log

Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target

Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target

康達信(Cantor Fitzgerald)重申對Structure Therapeutics的股票評級爲強於大盤(Overweight),維持其目標股價爲65美元。
Benzinga ·  08/15 08:21  · 評級/大行評級

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $65 price target.

Cantor Fitzgerald分析師Prakhar Agrawal重申Structure Therapeutics(納斯達克:GPCR)的股票評級爲超配,維持65美元的目標價格。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論